The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
Conditions
Breast
Phase III
Volunteers
Health Professionals
What is the purpose of this trial?
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
- Trial withAlliance for Clinical Trials in Oncology
- Start Date01/21/2022
- End Date01/01/2028
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Alessia Donadio, MD
- Andrea Brennan
- Andrea Martelli
- Andrea Silber, MD
- Anna Fleischman
- Armand Russo, MD
- Ashita Talsania, MRCP, MBBS
- Benjamin Newton, MD
- Brooke Chaves
- David Witt, MD
- Elizabeth Cappiello
- Emily Collier, MD
- Eric Winer, MD
- Ian Krop, MD, PhD
- Jade Vanacore
- James Vredenburgh, MD
- Jane Kanowitz, MD
- Jason Haldas, MD
- Javin Brita, PA
- Jeremy Kortmansky, MD
- Jose Morales-Marin
- Justin Persico, MD
- Karishma Mehra, MBBS
- Kathleen Fenn, MD
- Kathryn Daniels
- Kerin Adelson, MD
- Kert Sabbath, MD, FACP
- Kristen Hoxie
- Lajos Pusztai, MD, DPhil
- Madeline Santiago
- Mariya Rozenblit, MD
- Maryam Lustberg, MD, MPH
- Matthew Austin, MD
- Michael Cohenuram, MD
- Michael DiGiovanna, MD, PhD
- Michael Grant, MD
- Michelle Corso
- Navid Hafez, MD, MPH
- Pawan Karanam, MD
- Sara Anastasio, RN
- Sarah Elizabeth Schellhorn, MD
- Stephen Lattanzi, MD
- Tara Sanft, MD
- Victor Chang, MD
- Vidya Brown
- Virginia Syombathy
- Xuanthao Thi Nguyen
- Last Updated12/22/2022
- Study HIC#2000030282